8
Views
1
CrossRef citations to date
0
Altmetric
Research Article

A comparative study of two beta-blocker-diuretic combinations in the treatment of hypertension

, &
Pages 221-227 | Received 16 Apr 1986, Published online: 11 Aug 2008
 

Summary

Twenty patients with mild to severe essential hypertension completed a 12-week open crossover study to compare the effectiveness and tolerance of two beta-blocker/diuretic combinations. Patients were allocated at random to receive treatment for 6 weeks with either 40 mg propranolol plus 12.5 mg hydrochloro-thiazide twice daily or 400 mg acebutolol plus 25 mg hydrochlorothiazide once daily. They were then crossed over to the alternative medication for a further 6 weeks. Blood pressures and pulse rate were monitored in the supine and erect positions at regular intervals, as were side-effects, laboratory variables and ECG. The results showed that both combinations produced significant reductions from baseline in systolic and diastolic blood pressures but that the acebutolol combination produced a significantly greater reduction in diastolic blood pressure. There was no evidence of a treatment sequence effect. The two drug treatments were reasonably well tolerated, with a trend in favour of the acebutolol combination. No clinically significant changes were observed in any of the laboratory parameters investigated and there were no ECG abnormalities.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.